成都天视珍

Tianshizhen Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, dedicated to the discovery and development of long-acting biologics. The company utilizes a proprietary site-specific PEGylation platform to create next-generation therapeutic proteins and peptides with improved stability and extended half-lives. Its primary research focus lies in metabolic disorders, including type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). Tianshizhen's pipeline features several innovative candidates, such as long-acting GLP-1 receptor agonists and FGF21 analogues, aimed at reducing dosing frequency and improving patient compliance. The leadership team includes industry veterans with extensive experience in protein engineering and global drug development.